Wang, Xiaoxing http://orcid.org/0000-0001-6961-8667
Dowty, Martin E.
Tripathy, Sakambari
Le, Vu H.
Huh, Yeamin
Curto, Madelyn
Winton, Jennifer A.
O’Gorman, Melissa T.
Chan, Gary
Malhotra, Bimal K.
Funding for this research was provided by:
Pfizer Inc.
Article History
Accepted: 13 March 2024
First Online: 30 March 2024
Declarations
:
: All authors are employees and stockholders of Pfizer Inc.
: This research was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The final protocol, any amendments and informed consent documentation were reviewed and approved by the Independent Ethics Committee (Comite d'Ethique Hospitalo-Facultaire Erasme-ULB, Brussels, Belgium, for the midazolam DDI study in 2018; IntegReview Ethical Review Board, Austin, TX, USA, for the OC DDI study in 2018; Advarra, Columbia, MD, USA, for the cocktail DDI study in 2021) at the investigational center participating in the study.
: Written informed consent was obtained from all participants prior to enrollment.
: Not applicable.
: All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by XW, BM, MD, VHL, YH, MC, MO’G, JAW and GC. Bioanalytical data preparation and interpretation were performed by ST. VL: performed all statistical analyses of pharmacokinetic data. MC and GC: contributed to study safety. The first draft of the manuscript was written by XW; all authors critically reviewed the drafts and approved the final manuscript.